SCHEMBL5541449

SCHEMBL5541449

Fc1cccc(CCNc2cc[c]cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.57
GPR84 Q9NQS5 1/20 0.50
NOS1 P29475 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NOS3 P29474 1/20 0.46
CNR1 P21554 1/20 0.45
KDM4E B2RXH2 1/20 0.44
FFAR1 O14842 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
ADRA2A P08913 1/20 0.43
CHRM3 P20309 1/20 0.43
SLC6A2 P23975 1/20 0.43
HRH2 P25021 1/20 0.43
HTR2A P28223 1/20 0.43
HRH1 P35367 1/20 0.43
DRD3 P35462 1/20 0.43
HTR2B P41595 1/20 0.43
SLC6A3 Q01959 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535549 0.90 TAAR1 (0.50) TAAR1GPR84NOS1NOS3FFAR1
SCHEMBL5544344 0.85 FFAR1 (0.55) TAAR1NOS1L3MBTL1FFAR1
SCHEMBL3906108 0.84 L3MBTL1 (0.66) TAAR1GPR84NOS1L3MBTL1NOS3
SCHEMBL5537754 0.84 L3MBTL1 (0.41) TAAR1GPR84NOS1L3MBTL1NOS3
SCHEMBL5541615 0.82 TAAR1 (0.56) TAAR1GPR84L3MBTL1CNR1FFAR1
SCHEMBL5541806 0.82 TAAR1 (0.56) TAAR1GPR84NOS1L3MBTL1NOS3
SCHEMBL5544638 0.82 MAPT (0.49) TAAR1L3MBTL1CNR1
SCHEMBL15456313 0.80 TAAR1 (0.57) TAAR1SLC6A3
SCHEMBL5544020 0.80 L3MBTL1 (0.70) TAAR1L3MBTL1ADRA2ASLC6A2
SCHEMBL9114433 0.80 TAAR1 (0.57) TAAR1GPR84NOS1L3MBTL1NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TAAR1 364/4885GPR84 318/4885NOS1 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.